UBS Global Healthcare Conference
Logotype for Schrödinger Inc

Schrödinger (SDGR) UBS Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Schrödinger Inc

UBS Global Healthcare Conference summary

10 Nov, 2026

Platform and strategy

  • Molecular-discovery platform serves life sciences and a growing materials-science market; software licensing is the primary monetization model, alongside early-stage therapeutics, collaborations and NewCos.

  • Product development extends beyond small-molecule discovery into formulations and biologics, with continued platform advances and AI capabilities.

  • Physics-based simulation generates data to supplement limited experimental data for AI models; internal GPU capacity supports 30,000–40,000 accurate binding-affinity calculations daily for internal programs.

  • Accuracy, 30 years of development, more than $1 billion invested in the platform, and feedback from a 200-person therapeutics team were cited as competitive advantages.

Bunsen and AI adoption

  • Bunsen, an AI agent for running discovery workflows, had internal working versions more than a year ago; scientists validated it by Q4 last year, and it is currently in beta.

  • Bunsen aims to expand calculation throughput and make workflows more accessible; it can guide users, flag potential errors and support less experienced scientists, while still requiring expert oversight.

  • A typical pharma workflow could screen far more candidate molecules before selecting a smaller set for synthesis, potentially improving success probability and speeding discovery decisions.

  • Bunsen sessions can scale a computational chemist’s work across multiple concurrent tasks; results and experimental data can feed into LiveDesign to inform molecule selection.

  • Materials-science adoption is an opportunity: Bunsen could help individual users follow best practices and shorten service-led onboarding into software sales.

Software model and growth

  • Licensing is based on software instances and calculation throughput, not user seats; greater Bunsen usage is expected to drive demand for more licenses.

  • ACV is expected to increase 12%–17% this year from $198 million; growth spans top-20 pharma, other life-science and materials customers, new products and new customers.

  • Large pharma represents roughly half of commercial business; better biotech funding conditions also supported growth.

  • Bunsen has contributed to license growth while in beta; customers are evaluating it and completing security reviews, with further license-package uptake expected as adoption develops.

  • Predictive Tox had profiled 80 off-targets; further profiling is needed to increase customer utility, while Bunsen and other products continue to evolve.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Schrödinger